IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Novocure Limited. & Encourages Investors to Cont...
December 22 2016 - 5:57PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that it is
investigating claims against Novocure Limited. (“Novocure Limited”
or the “Company”) (Nasdaq: NVCR) concerning possible violations of
federal securities laws.
If you purchased shares of Novocure Limited. and want more
information free of charge, please contact Joon M. Khang, Esquire,
of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine,
CA 92612, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
Novocure designs and sells treatment for solid tumor cancers
therapy referred to as the tumor treating fields (“TTFields”).
Novocure markets its proprietary therapy, TTFields delivery system,
through the Optune name as a monotherapy treatment for adult
patients with glioblastoma brain cancer.
Novocure disclosed that its new Optune prescriptions fell to 657
in the second quarter from 755 in the first. Asaf Danziger, Chief
Executive Officer of Novocure, stated “[w]hile barriers to full
adoption remain, I am optimistic we will overcome the challenges
inherent in bringing a completely new therapy into widespread
clinical use.”
When this news was disclosed to the public, Novocure’s stock
dropped in value, causing investors severe harm.
If you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161222005823/en/
Joon M. Khang, Esq.Telephone: 949-419-3834Facsimile:
949-225-4474joon@khanglaw.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024